118 related articles for article (PubMed ID: 22056422)
21. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT.
Strojek K; Bebakar WM; Khutsoane DT; Pesic M; Smahelová A; Thomsen HF; Kalra S
Curr Med Res Opin; 2009 Dec; 25(12):2887-94. PubMed ID: 19821654
[TBL] [Abstract][Full Text] [Related]
22. Risk of breast cancer by individual insulin use: an international multicenter study.
Grimaldi-Bensouda L; Cameron D; Marty M; Barnett AH; Penault-Llorca F; Pollak M; Charbonnel B; Riddle M; Mignot L; Boivin JF; Khachatryan A; Rossignol M; Bénichou J; Alpérovitch A; Abenhaim L;
Diabetes Care; 2014; 37(1):134-43. PubMed ID: 23949559
[TBL] [Abstract][Full Text] [Related]
23. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden.
Jonasson JM; Ljung R; Talbäck M; Haglund B; Gudbjörnsdòttir S; Steineck G
Diabetologia; 2009 Sep; 52(9):1745-54. PubMed ID: 19588120
[TBL] [Abstract][Full Text] [Related]
24. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.
Cooke CE; Lee HY; Tong YP; Haines ST
Curr Med Res Opin; 2010 Jan; 26(1):231-8. PubMed ID: 19921965
[TBL] [Abstract][Full Text] [Related]
25. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.
Ashwell SG; Gebbie J; Home PD
Diabet Med; 2006 Aug; 23(8):879-86. PubMed ID: 16911626
[TBL] [Abstract][Full Text] [Related]
26. Insulin glargine use and breast cancer risk: Associations with cumulative exposure.
Peeters PJ; Bazelier MT; Leufkens HG; Auvinen A; van Staa TP; de Vries F; De Bruin ML
Acta Oncol; 2016 Jul; 55(7):851-8. PubMed ID: 27150973
[TBL] [Abstract][Full Text] [Related]
27. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
28. Insulin glargine in children aged 2 to 5 years.
Prescrire Int; 2013 Mar; 22(136):69. PubMed ID: 23593690
[TBL] [Abstract][Full Text] [Related]
29. Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells.
Mayer D; Chantelau E
Arch Physiol Biochem; 2010 May; 116(2):73-8. PubMed ID: 20199195
[TBL] [Abstract][Full Text] [Related]
30. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.
Colhoun HM;
Diabetologia; 2009 Sep; 52(9):1755-65. PubMed ID: 19603149
[TBL] [Abstract][Full Text] [Related]
31. Should we consider cancer diagnosis in diabetic patients as a complication of diabetes, or is it iatrogenic sequelae?
Tuomilehto J
Prim Care Diabetes; 2012 Apr; 6(1):1-2. PubMed ID: 22326674
[No Abstract] [Full Text] [Related]
32. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.
Hemkens LG; Grouven U; Bender R; Günster C; Gutschmidt S; Selke GW; Sawicki PT
Diabetologia; 2009 Sep; 52(9):1732-44. PubMed ID: 19565214
[TBL] [Abstract][Full Text] [Related]
33. Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies.
Wu JW; Filion KB; Azoulay L; Doll MK; Suissa S
Diabetes Care; 2016 Mar; 39(3):486-94. PubMed ID: 26740633
[TBL] [Abstract][Full Text] [Related]
34. Insulin glargine and risk of cancer: a meta-analysis.
Du X; Zhang R; Xue Y; Li D; Cai J; Zhou S; Huang Z; Yu R; Liu Y
Int J Biol Markers; 2012 Oct; 27(3):e241-6. PubMed ID: 22865296
[TBL] [Abstract][Full Text] [Related]
35. Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study.
Chang CH; Toh S; Lin JW; Chen ST; Kuo CW; Chuang LM; Lai MS
PLoS One; 2011; 6(6):e21368. PubMed ID: 21738645
[TBL] [Abstract][Full Text] [Related]
36. Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.
Tang X; Yang L; He Z; Liu J
PLoS One; 2012; 7(12):e51814. PubMed ID: 23284776
[TBL] [Abstract][Full Text] [Related]
37. Long-term exposure to insulin and volumetric mammographic density: observational and genetic associations in the Karma study.
Borgquist S; Rosendahl AH; Czene K; Bhoo-Pathy N; Dorkhan M; Hall P; Brand JS
Breast Cancer Res; 2018 Aug; 20(1):93. PubMed ID: 30092829
[TBL] [Abstract][Full Text] [Related]
38. Glargine safety, diabetes and cancer.
Rendell M; Akturk HK; Tella SH
Expert Opin Drug Saf; 2013 Mar; 12(2):247-63. PubMed ID: 23394441
[TBL] [Abstract][Full Text] [Related]
39. Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases.
Fagot JP; Blotière PO; Ricordeau P; Weill A; Alla F; Allemand H
Diabetes Care; 2013 Feb; 36(2):294-301. PubMed ID: 22966091
[TBL] [Abstract][Full Text] [Related]
40. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients.
Morden NE; Liu SK; Smith J; Mackenzie TA; Skinner J; Korc M
Diabetes Care; 2011 Sep; 34(9):1965-71. PubMed ID: 21775752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
